My Pathway: An Open Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents
Latest Information Update: 25 Jul 2024
At a glance
- Drugs Alectinib (Primary) ; Atezolizumab (Primary) ; Cobimetinib (Primary) ; Erlotinib (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary) ; Vemurafenib (Primary) ; Vismodegib (Primary)
- Indications Adenocarcinoma; Adrenocortical carcinoma; Biliary cancer; Bladder cancer; Breast cancer; Carcinoma; Cervical cancer; CNS cancer; Colon cancer; Colorectal cancer; Fallopian tube cancer; Gallbladder cancer; Gastric cancer; Head and neck cancer; Leiomyosarcoma; Liver cancer; Lung cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Salivary gland cancer; Sarcoma; Skin cancer; Soft tissue sarcoma; Solid tumours; Squamous cell cancer; Thyroid cancer; Tumours; Urogenital cancer; Uterine cancer
- Focus Therapeutic Use
- Acronyms Mypathway
- Sponsors Genentech
- 04 Oct 2023 Results (At data cutoff March 2022, n=346 ) assessing efficacy of Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid Tumors published in the Journal of Clinical Oncology
- 06 Jun 2023 Status changed from active, no longer recruiting to completed.
- 17 Mar 2023 Planned End Date changed from 29 Sep 2023 to 12 May 2023.